Bruxism Management During Dexamfetamine Therapy
Bruxism during dexamfetamine use is managed with a stepwise approach that prioritizes protection of teeth and reduction of contributing factors. Bruxism has been reported with multiple medication classes, including amphetamines, and drug-induced bruxism often has delayed onset after initiation. [1]
Medication Review and Dose-Modification Strategies
Medication contributors should be assessed through a focused medication reconciliation. Drug-induced bruxism is commonly reported as emerging within weeks after starting therapy, with a median time to symptom onset reported around 3–4 weeks in published case-based literature. [1]
Coordination with the prescribing clinician is recommended for any of the following medication strategies, based on reported management patterns for drug-induced bruxism:
- Dexamfetamine dose reduction
- Stimulant formulation change
- Switching to an alternative ADHD agent class
- Addressing timing of dosing to reduce peak stimulant exposure at bedtime [1]
A direct medication “anti-bruxism” prescription strategy is not established in high-quality bruxism guidelines for routine use. Published management for drug-induced bruxism is largely based on case reports, medication adjustments, and adjunctive symptomatic therapies. [1]
Dental Protection With Occlusal Splints (Night Guards)
A stabilization-type occlusal splint is recommended to reduce tooth wear and protect dental hard tissues in sleep bruxism. Occlusal splint therapy is supported as a viable treatment approach across comparative studies summarized in a systematic review. [2]
Splint use should be paired with dental follow-up to monitor:
- Tooth wear progression
- Temporomandibular joint and muscle symptoms
- Splint fit and wear patterns that can drive adjustment needs [3]
Behavioral and Self-Regulation Interventions
Stress and arousal factors are associated with bruxism expression. Behavioral strategies used in bruxism care commonly include cognitive and relaxation approaches and routine sleep-related behavioral measures. Bruxism - Sleep Education by American Academy of Sleep Medicine
Practice-based components that are commonly implemented in bruxism care (especially for awake bruxism) include:
- Regular jaw-relaxation training during the day
- Habit reversal strategies to interrupt clenching cycles
- Sleep hygiene optimization to reduce nighttime arousal triggers Bruxism - Sleep Education by American Academy of Sleep Medicine
Treatment of Muscle Pain and Refractory Cases
For persistent muscle pain or refractory symptoms despite occlusal protection and behavioral measures, chemodenervation can be considered by clinicians experienced in orofacial pain and TMJ care. Botulinum neurotoxin type A has been reviewed as a possible option for sleep bruxism to reduce symptoms and intensity of masseter activity in the setting of limited but supportive trial evidence. [4]
Evidence summaries of randomized trials have indicated reductions in pain outcomes and reductions in muscle contraction intensity for some sleep bruxism populations treated with botulinum toxin type A, with effects reported over follow-up periods such as ~12 weeks in individual trial findings aggregated in reviews. [5]
Symptom-Targeted Monitoring and Escalation
Monitoring should focus on functional harm rather than bruxism awareness alone. Dental sequelae monitoring is central because bruxism contributes to tooth wear and restorative risk, including in drug-associated cases. [1]
Escalation is indicated when any of the following are present:
- Rapid progression of tooth wear or fractures
- Persistent masseter or TMJ pain
- Sleep disruption with daytime consequences
- Inadequate response to splint protection plus behavioral interventions [3]
Practical Action Plan for Dexamphetamine-Associated Bruxism
Medication and symptomatic care should be executed in parallel:
- Confirm bruxism type (awake vs sleep bruxism) through history because management emphasis differs. Bruxism - Sleep Education by American Academy of Sleep Medicine
- Protect dentition with a stabilization occlusal splint and arrange dental follow-up. [3]
- Coordinate with the prescribing clinician to adjust dexamfetamine exposure (dose, timing, or agent class change) because drug-induced bruxism is commonly temporally linked to stimulant initiation. [1]
- Implement behavioral relaxation and habit interruption strategies with sleep hygiene support. Bruxism - Sleep Education by American Academy of Sleep Medicine
- Consider botulinum toxin type A for persistent, function-limiting symptoms after failure of conservative measures under specialty care. [4]
Common Pitfalls to Avoid
Occlusal splints and behavioral changes should not be delayed when dental injury is present. Bruxism can be medication-associated and can persist until the contributing factor is modified. [1]
Medication changes should not be performed without prescriber coordination. Amphetamine-associated bruxism often follows stimulant initiation timing, and management typically relies on dose or agent adjustments rather than self-directed discontinuation. [1]